Business Context and Reporting Period
Company: Integra LifeSciences Holdings Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: September 8, 2026
Reporting Period: Event-based report dated September 8, 2026.
The filing serves as a Regulation FD disclosure to furnish an updated investor presentation (Exhibit 99.1) intended for use in discussions with existing or prospective lenders.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses on the disclosure of an investor presentation rather than reporting specific financial results for the period.
Material Changes
No material changes to financial performance or operational status are detailed in the text of this filing. The primary activity reported is the update of investor materials related to financing plans.
Guidance, Outlook, and Management Commentary
- Refinancing Plans: The Company is utilizing the attached investor presentation in connection with previously disclosed plans to refinance its outstanding senior credit facility in 2026.
- Legal Disclaimer: The information in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liability of such section. It is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Investor Presentation) for specific details on the proposed refinancing terms and financial projections.
- Verify the status of the outstanding senior credit facility and the timeline for the 2026 refinancing.
- Confirm whether the investor presentation contains forward-looking statements that differ from prior public guidance.
- Check subsequent filings for the final terms of the refinancing agreement once executed.